ceftazidime

Summary

Summary: Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.

Top Publications

  1. Williamson D, Roberts S, Smith M, Heffernan H, Tiong A, Pope C, et al. High rates of susceptibility to ceftazidime among globally prevalent CTX-M-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. Eur J Clin Microbiol Infect Dis. 2012;31:821-4 pubmed publisher
    ..Whereas under previous CLSI recommendations all isolates in this strain collection would have been reported as ceftazidime-resistant, under the new recommendations, approximately 11% of CTX-M-15-producing E...
  2. Hocquet D, Colomb M, Dehecq B, Belmonte O, Courvalin P, Plesiat P, et al. Ceftazidime-hydrolysing ?-lactamase OXA-145 with impaired hydrolysis of penicillins in Pseudomonas aeruginosa. J Antimicrob Chemother. 2011;66:1745-50 pubmed publisher
    ..The deletion of Leu-165 is responsible for a shift in the hydrolysis spectrum from penicillins to third-generation cephalosporins, as well as monobactams. The loss of penicillin hydrolysis was due to a non-carboxylated Lys-73. ..
  3. Walkty A, DeCorby M, Lagacé Wiens P, Karlowsky J, Hoban D, Zhanel G. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011;55:2992-4 pubmed publisher
    The in vitro activity of ceftazidime in combination with NXL104 versus 470 Pseudomonas aeruginosa clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods...
  4. Livermore D, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55:390-4 pubmed publisher
    Combinations of NXL104 with ceftazidime and aztreonam were tested against carbapenem-resistant members of the Enterobacteriaceae...
  5. Guthrie K, Yong M, Frieze D, Corey L, Fredricks D. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010;45:675-81 pubmed publisher
    ..compared the clinical and microbiological impact of a change in antibiotic prophylaxis practice from ceftazidime (n=216 patients with HCT in 2000-2002) to levofloxacin (n=219 patients, August 2002-2005) in patients receiving ..
  6. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother. 2009;53:3650-6 pubmed publisher
    ..crossover study compared the safety and efficacy of continuous infusion with those of short infusions of ceftazidime in patients with cystic fibrosis...
  7. Novais A, Canton R, Coque T, Moya A, Baquero F, Galan J. Mutational events in cefotaximase extended-spectrum beta-lactamases of the CTX-M-1 cluster involved in ceftazidime resistance. Antimicrob Agents Chemother. 2008;52:2377-82 pubmed publisher
    ..place due to the appearance of more efficient enzymes which are capable of hydrolyzing both cefotaxime and ceftazidime, especially among the CTX-M-1 cluster...
  8. Eumkeb G, Sakdarat S, Siriwong S. Reversing ?-lactam antibiotic resistance of Staphylococcus aureus with galangin from Alpinia officinarum Hance and synergism with ceftazidime. Phytomedicine. 2010;18:40-5 pubmed publisher
    ..The antibacterial, synergy effects and primary mechanism of action of galangin and ceftazidime against S...
  9. Elsner J, Shefy Peleg A, Zilberman M. Novel biodegradable composite wound dressings with controlled release of antibiotics: microstructure, mechanical and physical properties. J Biomed Mater Res B Appl Biomater. 2010;93:425-35 pubmed publisher
    ..on the microstructure, mechanical and physical properties, and the release profile of the antibiotic drug ceftazidime from the binding matrix...

More Information

Publications69

  1. Schneider I, Queenan A, Markovska R, Markova B, Keuleyan E, Bauernfeind A. New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria. Antimicrob Agents Chemother. 2009;53:4518-21 pubmed publisher
    ..This exchange decreased the hydrolytic activity of the beta-lactamase for cefotaxime, ceftazidime, and cefepime.
  2. Ferrari F, Liu Z, Lu Q, Becquemin M, Louchahi K, Aymard G, et al. Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med. 2008;34:1718-23 pubmed publisher
    ..the efficiency of an Aeroneb Pro vibrating plate and an Atomisor MegaHertz ultrasonic nebulizer for providing ceftazidime distal lung deposition. In vitro experiments...
  3. LaPlante K, Sakoulas G. Evaluating aztreonam and ceftazidime pharmacodynamics with Escherichia coli in combination with daptomycin, linezolid, or vancomycin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2009;53:4549-55 pubmed publisher
    In an in vitro pharmacodynamic model, linezolid attenuated the activity of aztreonam and ceftazidime against Escherichia coli...
  4. Qing Y, Cao K, Fang Z, Huang Y, Zhang X, Tian G, et al. Outbreak of PER-1 and diversity of ?-lactamases among ceftazidime-resistant Pseudomonas aeruginosa clinical isolates. J Med Microbiol. 2014;63:386-92 pubmed publisher
    ..The aim of this study was to investigate the diversity of ?-lactamases in the collection of 51 ceftazidime-resistant P. aeruginosa clinical isolates in four hospitals of southern China...
  5. Metallidis S, Kollaras P, Giannakakis T, Seitanidis B, Kordosis T, Nikolaidis J, et al. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic pati. Eur J Intern Med. 2008;19:619-24 pubmed publisher
    ..the efficacy, safety, and cost of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in neutropenic febrile patients...
  6. Lorente L, Jimenez A, Palmero S, Jiménez J, Iribarren J, Santana M, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther. 2007;29:2433-9 pubmed
    ..However, there are limited data on the clinical efficacy of ceftazidime administered by continuous infusion...
  7. Rossolini G, D Andrea M, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect. 2008;14 Suppl 1:33-41 pubmed
    ..CTX-M-type ESBLs exhibit powerful activity against cefotaxime and ceftriaxone but generally not against ceftazidime, which has important implications for laboratory detection...
  8. Behera B, Prasad Babu T, Kamalesh A, Reddy G. Ceftazidime resistance in Burkholderia pseudomallei: first report from India. Asian Pac J Trop Med. 2012;5:329-30 pubmed publisher
    ..pesudomallei), sensitive to carbapenem, co-trimoxazole and resistant to ceftazidime. The patient was successfully treated with imipenem- cilastin...
  9. Antunes N, Frase H, Toth M, Mobashery S, Vakulenko S. Resistance to the third-generation cephalosporin ceftazidime by a deacylation-deficient mutant of the TEM ?-lactamase by the uncommon covalent-trapping mechanism. Biochemistry. 2011;50:6387-95 pubmed publisher
    ..coli TEM(pTZ19-3) ?-lactamase produces a 128-fold increase in the level of resistance to the antibiotic ceftazidime in comparison to that of the parental wild-type enzyme...
  10. Taccone F, Laterre P, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient ?-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:R126 pubmed publisher
    ..The aim of our study was to determine whether the first dose of piperacillin-tazobactam, ceftazidime, cefepime, and meropenem would result in adequate serum drug concentrations in patients with severe sepsis and ..
  11. Queenan A, Shang W, Bush K, Flamm R. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrob Agents Chemother. 2010;54:4092-7 pubmed publisher
    Single-step Pseudomonas aeruginosa mutants, selected with ceftobiprole, ceftazidime, or cefepime, were generated at frequencies of 10(-6) to <10(-9) at two and four times the MIC...
  12. Cheng A. Melioidosis: advances in diagnosis and treatment. Curr Opin Infect Dis. 2010;23:554-9 pubmed publisher
    ..Since the original trials defining setting the standard of care as ceftazidime, no antibiotic regimens have been shown to be superior in comparative trials, but ongoing trials are evaluating ..
  13. Lautenbach E, Marsicano R, Tolomeo P, Heard M, Serrano S, Stieritz D. Epidemiology of antimicrobial resistance among gram-negative organisms recovered from patients in a multistate network of long-term care facilities. Infect Control Hosp Epidemiol. 2009;30:790-3 pubmed publisher
    ..of fluoroquinolone resistance in Escherichia coli was 51% (446 of 874 isolates), whereas the prevalences of ceftazidime and imipenem resistance in Klebsiella species were 26% and 6% (84 and 19 of 323 isolates), respectively...
  14. Noel G, Bush K, Bagchi P, Ianus J, Strauss R. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46:647-55 pubmed publisher
    ..or gram-negative bacteria was conducted to compare ceftobiprole monotherapy with treatment with vancomycin plus ceftazidime. Patients were randomized 2:1 to receive ceftobiprole or to receive vancomycin plus ceftazidime...
  15. Hocquet D, Plesiat P, Dehecq B, Mariotte P, Talon D, Bertrand X. Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. Antimicrob Agents Chemother. 2010;54:3512-5 pubmed publisher
    ..ES-OXAs) in a French collection of 140 clinical Pseudomonas aeruginosa isolates highly resistant to ceftazidime. Six ESBLs (PER-1, n=3; SHV-2a, n=2; VEB-1a, n=1), four MBLs (VIM-2, n=3; IMP-18, n=1), and five ES-OXAs (OXA-..
  16. Zarogoulidis P, Kioumis I, Ritzoulis C, Petridis D, Darwiche K, Porpodis K, et al. New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam. Int J Pharm. 2013;455:182-8 pubmed publisher
    ..ml (8 ml only for large residual cups) with five different antibiotic drugs (ampicilln-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam)...
  17. Crandon J, Schuck V, Banevicius M, Beaudoin M, Nichols W, Tanudra M, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:6137-46 pubmed publisher
    The combination of ceftazidime and avibactam possesses potent activity against resistant Gram-negative pathogens, including Pseudomonas aeruginosa...
  18. McKinnon P, Paladino J, Schentag J. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345-51 pubmed publisher
    ..with clinical and microbiological outcomes in patients with bacteraemia and sepsis treated with cefepime or ceftazidime. Pharmacokinetic and pharmacodynamic parameters were derived for 76 of 107 patients enrolled in two prospective,..
  19. Bandeira T, Moreira C, Brilhante R, Castelo Branco D, Neto M, Cordeiro R, et al. In vitro activities of amoxicillin-clavulanate, doxycycline, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole against biofilm of Brazilian strains of Burkholderia pseudomallei. Antimicrob Agents Chemother. 2013;57:5771-3 pubmed publisher
    This study aimed at investigating the in vitro activities of amoxicillin-clavulanate, doxycycline, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole against Burkholderia pseudomallei in planktonic and biofilm forms, through broth ..
  20. Mushtaq S, Warner M, Livermore D. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010;65:2376-81 pubmed publisher
    NXL104 potentiates ceftazidime and ceftaroline against Enterobacteriaceae with extended-spectrum, AmpC, KPC and OXA ?-lactamases...
  21. Judy B, Whitlock G, Torres A, Estes D. Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin. BMC Microbiol. 2009;9:88 pubmed publisher
    ..The effect of two antibiotics with different modes of action on Burkholderia mallei strain ATCC23344 was investigated by using in vitro and in vivo studies...
  22. Maybauer M, Maybauer D, Fraser J, Westphal M, Szabo C, Cox R, et al. Combined recombinant human activated protein C and ceftazidime prevent the onset of acute respiratory distress syndrome in severe sepsis. Shock. 2012;37:170-6 pubmed publisher
    ..animal study investigates the effects of combined recombinant human activated protein C (rhAPC) and ceftazidime on cardiopulmonary function in acute lung injury and severe sepsis...
  23. Chantratita N, Rholl D, Sim B, Wuthiekanun V, Limmathurotsakul D, Amornchai P, et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A. 2011;108:17165-70 pubmed publisher
    ..Burkholderia pseudomallei (the cause of melioidosis), associated with treatment failure during prolonged ceftazidime therapy of natural infection...
  24. Hosoglu S, Gundes S, Kolayli F, Karadenizli A, Demirdag K, Gunaydin M, et al. Extended-spectrum beta-lactamases in ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae isolates in Turkish hospitals. Indian J Med Microbiol. 2007;25:346-50 pubmed
    ..of TEM-, SHV- and GES-type beta -lactamases among Escherichia coli and Klebsiella pneumoniae strains having ceftazidime MICs higher than 2 mg/L. A total of 63 E. coli and 41 K...
  25. Wuthiekanun V, Amornchai P, Saiprom N, Chantratita N, Chierakul W, Koh G, et al. Survey of antimicrobial resistance in clinical Burkholderia pseudomallei isolates over two decades in Northeast Thailand. Antimicrob Agents Chemother. 2011;55:5388-91 pubmed publisher
    ..6%) patients with one or more isolates resistant to ceftazidime (n = 8), amoxicillin-clavulanic acid (n = 4), or both drugs (n = 12)...
  26. Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette C, Wallet F, et al. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med. 2009;35:1792-800 pubmed publisher
    Ventilator-associated pneumonia caused by Pseudomonas aeruginosa with impaired sensitivity to ceftazidime is frequent in critically ill patients...
  27. Sam I, See K, Puthucheary S. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J Clin Microbiol. 2009;47:1556-8 pubmed publisher
    A patient with a clonal infection of Burkholderia pseudomallei had subpopulations with ceftazidime and amoxicillin-clavulanate susceptibilities that differed among the clinical specimens...
  28. Riedele C, Reichl U. Interspecies effects in a ceftazidime-treated mixed culture of Pseudomonas aeruginosa, Burkholderia cepacia and Staphylococcus aureus: analysis at the single-species level. J Antimicrob Chemother. 2011;66:138-45 pubmed publisher
    ..In the study presented here, the effect of ceftazidime against a model microbial community consisting of Pseudomonas aeruginosa, Burkholderia cepacia and ..
  29. Georges B, Conil J, Seguin T, Ruiz S, Minville V, Cougot P, et al. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother. 2009;53:4483-9 pubmed publisher
    The aim of this study was to develop a population-pharmacokinetic model of ceftazidime in intensive care unit patients to include the influence of patients' characteristics on the pharmacokinetics...
  30. Lu Q, Yang J, Liu Z, Gutiérrez C, Aymard G, Rouby J. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;184:106-15 pubmed publisher
    ..To assess the efficacy and safety of nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa...
  31. Nagano Y, Nagano N, Wachino J, Ishikawa K, Arakawa Y. Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. Antimicrob Agents Chemother. 2009;53:69-74 pubmed publisher
    ..identified in Shigella sonnei strain UIH-1, which exhibited resistance to cefotaxime (MIC, 1,024 microg/ml) and ceftazidime (MIC, 32 microg/ml)...
  32. Croisier D, Martha B, Piroth L, Chavanet P. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia. Int J Antimicrob Agents. 2008;32:494-8 pubmed publisher
    In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits...
  33. Doublet B, Granier S, Robin F, Bonnet R, Fabre L, Brisabois A, et al. Novel plasmid-encoded ceftazidime-hydrolyzing CTX-M-53 extended-spectrum beta-lactamase from Salmonella enterica serotypes Westhampton and Senftenberg. Antimicrob Agents Chemother. 2009;53:1944-51 pubmed publisher
    ..Westhampton and one of serotype Senftenberg) resistant to extended-spectrum cephalosporins (cefotaxime and ceftazidime) were recovered in 2004 from living cockles in three supermarkets located in distant geographic areas in France,..
  34. Campo Esquisabel A, Rodriguez M, Campo Sosa A, Rodriguez C, Martinez Martinez L. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime. Clin Microbiol Infect. 2011;17:1817-22 pubmed publisher
    The MIC of cefepime determined with the MicroScan WalkAway system was ?2 times higher than that of ceftazidime for 105 clinical isolates of Pseudomonas aeruginosa. This phenotype was confirmed by reference microdilution in 68 (64...
  35. Limmathurotsakul D, Peacock S. Melioidosis: a clinical overview. Br Med Bull. 2011;99:125-39 pubmed publisher
    ..Melioidosis, an infection caused by the environmental Gram-negative bacillus Burkholderia pseudomallei, has emerged as an important cause of morbidity and mortality in Southeast Asia and northern Australia...
  36. Aubert G, Carricajo A, Coudrot M, Guyomarc h S, Auboyer C, Zeni F. Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit. 2010;32:517-9 pubmed publisher
    The purpose of this study was to assess the value of a serum assay for ceftazidime (CAZ) in patients in the intensive care unit (ICU) of the Saint-Etienne University Teaching Hospital and in other ICUs in the region to optimize therapy...
  37. Raju B, Bali T, Thiagarajan G, Rao V, Das T, Sharma S. Physicochemical properties and antibacterial activity of the precipitate of vancomycin and ceftazidime: implications in the management of endophthalmitis. Retina. 2008;28:320-5 pubmed publisher
    To study the physicochemical properties, bioavailability, and microbicidal activity of vancomycin and ceftazidime in the precipitate formed by the drugs in mixture. The precipitation of the drugs prepared in buffers in the pH range of 5...
  38. Pena C, Suarez C, Tubau F, Juan C, Moya B, Dominguez M, et al. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase. J Clin Microbiol. 2009;47:2381-7 pubmed publisher
    Cefepime (FEP) and ceftazidime (CAZ) are broad-spectrum cephalosporins that display similar MICs for wild-type Pseudomonas aeruginosa strains. Recently, P...
  39. Ding F, Zarlenga D, Ren Y, Li G, Luan J, Ren X. Use of the D-R model to define trends in the emergence of Ceftazidime-resistant Escherichia coli in China. PLoS ONE. 2011;6:e27295 pubmed publisher
    To assess the efficacy of the D-R model for defining trends in the appearance of Ceftazidime-resistant Escherichia coli. Actual data related to the manifestation of Ceftazidime-resistant E...
  40. Levasseur P, Girard A, Claudon M, Goossens H, Black M, Coleman K, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56:1606-8 pubmed publisher
    ..The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa isolates...
  41. Sarovich D, Price E, Von Schulze A, Cook J, Mayo M, Watson L, et al. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS ONE. 2012;7:e30789 pubmed publisher
    ..if not treated with a specific antibiotic regimen, which typically includes the third-generation cephalosporin, ceftazidime (CAZ). There have been several resistance mechanisms described for B...
  42. Lee K, Lee M, Lee C, Lee J, Roh K, Kim S, et al. Increase of ceftazidime- and fluoroquinolone-resistant Klebsiella pneumoniae and imipenem-resistant Acinetobacter spp. in Korea: analysis of KONSAR study data from 2005 and 2007. Yonsei Med J. 2010;51:901-11 pubmed publisher
    ..We analyzed antimicrobial resistance data generated by Korean Hospitals and by a commercial laboratory in 2005 and 2007...
  43. Zurowska A, Feneberg R, Warady B, Zimmering M, Monteverde M, Testa S, et al. Gram-negative peritonitis in children undergoing long-term peritoneal dialysis. Am J Kidney Dis. 2008;51:455-62 pubmed publisher
    ..A substantial proportion (20%) of organisms were resistant to ceftazidime, with resulting suboptimal response to empirical therapy...
  44. Scotta C, Bennasar A, Moore E, Lalucat J, Gomila M. Taxonomic characterisation of ceftazidime-resistant Brevundimonas isolates and description of Brevundimonas faecalis sp. nov. Syst Appl Microbiol. 2011;34:408-13 pubmed publisher
    Three ceftazidime-resistant strains isolated from the sewage water of a municipal hospital in Palma de Mallorca, Spain, were analysed phenotypically and genotypically to clarify their taxonomic positions...
  45. Lucasti C, Popescu I, Ramesh M, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68:1183-92 pubmed publisher
    Avibactam, a novel non-?-lactam ?-lactamase inhibitor, restores the in vitro activity of ceftazidime against class A, C and some class D ?-lactamase-producing pathogens, including those commonly associated with complicated intra-..
  46. Kurokawa H, Yagi T, Shibata N, Shibayama K, Kamachi K, Arakawa Y. A new SHV-derived extended-spectrum beta-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the -loop. Antimicrob Agents Chemother. 2000;44:1725-7 pubmed
    A new SHV-derived extended-spectrum beta-lactamase (SHV-24) conferring high-level resistance to ceftazidime but not cefotaxime and cefazolin was identified in Japan...
  47. Blumer J, Saiman L, Konstan M, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest. 2005;128:2336-46 pubmed
    ..We report on a blinded comparative trial of IV meropenem (40 mg/kg to 2 g q8h) or ceftazidime (5 mg/kg to 2 g q8h), each of which was administered with IV tobramycin (at a serum peak of > or = 8 microg/..
  48. Lui S, Cheng S, Ng F, Ng S, Wan K, Yip T, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int. 2005;68:2375-80 pubmed
    ..for continuous ambulatory peritoneal dialysis (CAPD) peritonitis 2000 recommended the use of cefazolin plus ceftazidime as the initial empirical therapy in patients with residual renal function (RRF)...
  49. Bagge N, Ciofu O, Skovgaard L, Høiby N. Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing Pseudomonas aeruginosa due to chromosomal beta-lactamase. APMIS. 2000;108:589-600 pubmed
    ..aeruginosa during treatment with ceftazidime. Biofilms were established in vitro using a modified Robbins device (MRD) and in vivo in the rat model of ..
  50. Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin Infect Dis. 2001;33:29-34 pubmed
    ..plus cotrimoxazole (trimethoprim-sulfamethoxazole [TMP-SMZ] at a ratio of 80:400; TMP, 8 mg/kg/day) versus ceftazidime (100 mg/kg/day) plus cotrimoxazole (TMP, 8 mg/kg/day) for the treatment of severe melioidosis...
  51. Vahaboglu H, Budak F, Kasap M, Gacar G, Torol S, Karadenizli A, et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother. 2006;58:537-42 pubmed
    ..Since these isolates are highly resistant to antibiotics this finding indicates the existence of a significant problem in Turkish hospitals. ..
  52. Egerer G, Goldschmidt H, Hensel M, Harter C, Schneeweiss A, Ehrhard I, et al. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002;30:427-31 pubmed
    This prospective study was performed to examine the safety and efficacy of a continuous infusion of ceftazidime in patients who developed febrile neutropenia after high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell ..
  53. Ho P, Cheung T, Yam W, Yuen K. Characterization of a laboratory-generated variant of BPS beta-lactamase from Burkholderia pseudomallei that hydrolyses ceftazidime. J Antimicrob Chemother. 2002;50:723-6 pubmed
    ..The beta-lactamase gene from a laboratory-derived, ceftazidime-resistant strain of B. pseudomallei (LH-1-2) was cloned and expressed in Escherichia coli...
  54. Roberts J, Webb S, Lipman J. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. Int J Antimicrob Agents. 2007;29:117-28 pubmed
    ..Cefepime and ceftazidime are broad-spectrum cephalosporins that are widely used to treat Gram-negative nosocomial infections in ..
  55. Lubasch A, Luck S, Lode H, Mauch H, Lorenz J, Bölcskei P, et al. Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis. J Antimicrob Chemother. 2003;51:659-64 pubmed
    ..the clinical and bacteriological outcome and pharmacokinetic as well as pharmacodynamic parameters of two ceftazidime therapy regimens in patients with acute exacerbation of severe chronic bronchitis (AECB)...
  56. Baraniak A, Fiett J, Hryniewicz W, Nordmann P, Gniadkowski M. Ceftazidime-hydrolysing CTX-M-15 extended-spectrum beta-lactamase (ESBL) in Poland. J Antimicrob Chemother. 2002;50:393-6 pubmed
    ..identified in Enterobacteriaceae isolates in India, and demonstrated significant hydrolytic activity against ceftazidime, in contrast to the majority of CTX-M enzymes...
  57. Boselli E, Breilh D, Rimmelé T, Poupelin J, Saux M, Chassard D, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004;30:989-91 pubmed
    To determine the steady-state plasma and epithelial lining fluid (ELF) concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Prospective, open-label study...
  58. Matzke G, Frye R, Joy M, Palevsky P. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2000;44:1639-44 pubmed
    ..adjustment regimens have been proposed, there is little quantitative information to guide the initiation of ceftazidime therapy in patients who are receiving continuous renal replacement therapy...
  59. Mouithys Mickalad A, Mathy Hartert M, Du G, Sluse F, Deby C, Lamy M, et al. Oxygen consumption and electron spin resonance studies of free radical production by alveolar cells exposed to anoxia: inhibiting effects of the antibiotic ceftazidime. Redox Rep. 2002;7:85-94 pubmed
    ..production by cultured human alveolar cells subjected to anoxia/re-oxygenation (A/R), and tested the effects of ceftazidime, an antibiotic previously demonstrated to possess antioxidant properties...
  60. Mimoz O, Leotard S, Jacolot A, Padoin C, Louchahi K, Petitjean O, et al. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. Antimicrob Agents Chemother. 2000;44:885-90 pubmed
    The antibacterial activities of imipenem-cilastatin, meropenem-cilastatin, cefepime and ceftazidime against Enterobacter cloacae NOR-1, which produces the carbapenem-hydrolyzing beta-lactamase NmcA and a cephalosporinase, and against one ..